@silouanwinter
Interested is not really the word!
Forced to live with the risk and all the medical examinations is what people (female AND male) endure. #BRCA

🇩🇪Gibts hier andere, die sich auch mit #brca #mastektomie und #eierstockentfernung #ovarektomie beschäftigen? Gerne boosten! 🇬🇧Are there others here interested in #brca,
#mastectomy? Boosts appreciated

🇩🇪Gibts hier andere, die sich auch mit #brca #mastektomie und #eierstockentfernung #ovarektomie beschäftigen? Gerne boosten! 🇬🇧Are there others here interested in #brca,
#mastectomy or #ovarectomy? Boosts appreciated

So … the explanation for my breast cancer more than a decade ago (aged 35) is the BRCA-1 mutation. Splendid. Seems like I’m gonna get rid of my ovaries and boobs this year because once is enough. #brca #fckcancer

RT @DebHarkness
Today's gratitude:
🖼️ windows that look like still life paintings
👙 the bralette my beloved Julie gave me so I could focus on the exciting lingerie possibilities awaiting me after my double mastectomy #LivingWithOvarianCancer #BRCA
🗻 snowy mountains
#simplethings #gratitude

I thought knowing I had the ‘cancer gene’ would cast a shadow over my life. Now I have it, I realise how wrong I was https://www.theguardian.com/commentisfree/2023/feb/06/breast-cancer-gene-family-disease-knowlege?CMP=Share_AndroidApp_Other

#BRCA

RT @jane_meisel
@HHampel1 @JohnEbbenMDPhD @drteplinsky @quirogad @TumorBoardTues @MPishvaian @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @HannahAlison20 @HHampel1 definitely agree. But also important for patients to know that it's not only Ashkenazi Jews who are #BRCA+ ....I feel like I am often dispelling that myth when I encourage patients to test!

RT @jane_meisel
@MPishvaian @JohnEbbenMDPhD @quirogad @TumorBoardTues @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert All HER2- #mbc patients should be tested because if positive, PARPis can be incorporated into their #treatment algorithms. Options for #ClinicalTrials may change based on #BRCA status as well @WinshipAtEmory

RT @quirogad
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @MarkRobsonMD @US_FDA @drjennifergao @FDAOncology 9/14 #TumorBoardTuesday #BRCA
👩🏽‍🏫Mini tweetorial 7👩🏻‍🏫

🏷@US_FDA drug labels 👇🏽

👍🏽Olaparib https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf
👍🏽Talazoparib https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf

RT @quirogad
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert 5/17 #TumorBoardTuesday #BRCA
👩🏽‍🏫Mini tweetorial 3👩🏻‍🏫

🇬🇷OLYMPIAD🇬🇷

🔸Phase III RCT olaparib vs physician’s choice chemo
🔸HER2-neg MBC
🔸Germline BRCA1/2 mut
🔸2 ≥ prior chemos
📚https://www.nejm.org/doi/full/10.1056/nejmoa1706450
@MarkRobsonMD

RT @quirogad
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @MarkRobsonMD 8/17 #TumorBoardTuesday #BRCA
👩🏽‍🏫Mini tweetorial 6👩🏻‍🏫

🎉@US_FDA Olaparib👍🏽for gBRCA1/2 mut MBC (Jan 2018)
🎉Talazoparib 👍🏽 for gBRCA1/2 mut MBC (Oct 2018)

📍No restrictions which line of tx
🧪BRACAnalysis CDx test 👍🏽 as @US_FDA companion diagnostic
@drjennifergao @FDAOncology

RT @quirogad
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @MarkRobsonMD @US_FDA @drjennifergao @FDAOncology 9/14 #TumorBoardTuesday #BRCA
👩🏽‍🏫Mini tweetorial 7👩🏻‍🏫

🏷@US_FDA drug labels 👇🏽

👍🏽Olaparib https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf
👍🏽Talazoparib https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf

RT @jane_meisel
@MPishvaian @JohnEbbenMDPhD @quirogad @TumorBoardTues @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert All HER2- #mbc patients should be tested because if positive, PARPis can be incorporated into their #treatment algorithms. Options for #ClinicalTrials may change based on #BRCA status as well @WinshipAtEmory

RT @quirogad
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert 5/17 #TumorBoardTuesday #BRCA
👩🏽‍🏫Mini tweetorial 3👩🏻‍🏫

🇬🇷OLYMPIAD🇬🇷

🔸Phase III RCT olaparib vs physician’s choice chemo
🔸HER2-neg MBC
🔸Germline BRCA1/2 mut
🔸2 ≥ prior chemos
📚https://www.nejm.org/doi/full/10.1056/nejmoa1706450
@MarkRobsonMD

RT @quirogad
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @MarkRobsonMD 8/17 #TumorBoardTuesday #BRCA
👩🏽‍🏫Mini tweetorial 6👩🏻‍🏫

🎉@US_FDA Olaparib👍🏽for gBRCA1/2 mut MBC (Jan 2018)
🎉Talazoparib 👍🏽 for gBRCA1/2 mut MBC (Oct 2018)

📍No restrictions which line of tx
🧪BRACAnalysis CDx test 👍🏽 as @US_FDA companion diagnostic
@drjennifergao @FDAOncology

RT @quirogad
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @MarkRobsonMD @US_FDA @drjennifergao @FDAOncology 9/14 #TumorBoardTuesday #BRCA
👩🏽‍🏫Mini tweetorial 7👩🏻‍🏫

🏷@US_FDA drug labels 👇🏽

👍🏽Olaparib https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf
👍🏽Talazoparib https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf

RT @jane_meisel
@HHampel1 @JohnEbbenMDPhD @drteplinsky @quirogad @TumorBoardTues @MPishvaian @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @HannahAlison20 @HHampel1 definitely agree. But also important for patients to know that it's not only Ashkenazi Jews who are #BRCA+ ....I feel like I am often dispelling that myth when I encourage patients to test!

RT @jane_meisel
@HHampel1 @JohnEbbenMDPhD @drteplinsky @quirogad @TumorBoardTues @MPishvaian @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @HannahAlison20 @HHampel1 definitely agree. But also important for patients to know that it's not only Ashkenazi Jews who are #BRCA+ ....I feel like I am often dispelling that myth when I encourage patients to test!

RT @jane_meisel
@MPishvaian @JohnEbbenMDPhD @quirogad @TumorBoardTues @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert All HER2- #mbc patients should be tested because if positive, PARPis can be incorporated into their #treatment algorithms. Options for #ClinicalTrials may change based on #BRCA status as well @WinshipAtEmory

RT @quirogad
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert 5/17 #TumorBoardTuesday #BRCA
👩🏽‍🏫Mini tweetorial 3👩🏻‍🏫

🇬🇷OLYMPIAD🇬🇷

🔸Phase III RCT olaparib vs physician’s choice chemo
🔸HER2-neg MBC
🔸Germline BRCA1/2 mut
🔸2 ≥ prior chemos
📚https://www.nejm.org/doi/full/10.1056/nejmoa1706450
@MarkRobsonMD